SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of the sentinel cohort of its Phase 2b clinical trial evaluating Vaxart’s ...
Results that may be inaccessible to you are currently showing.